Skip to main content
. 2022 Dec 13;14(24):6142. doi: 10.3390/cancers14246142

Figure 1.

Figure 1

MERTK and BCL-2 mRNA and protein are preferentially expressed in ETP-ALL compared to non-ETP T-ALL. (A,B) Publicly available gene expression data from the TARGET program were analyzed to determine the relative expression of MERTK (A) or BCL-2 (B) in pediatric ETP-ALL and non-ETP T-ALL patient samples. mRNA read counts were normalized to the mean mRNA read count in the non-ETP T-ALL samples and the distribution was compared using an unpaired t-test. (C,D) Whole-cell lysates from a panel of T-ALL and ETP-ALL cell lines were probed for MERTK (C) or BCL-2 (D) expression by immunoblot. Tubulin was used as a loading control. Images shown are representative of at least three independent experiments. (E) Whole-cell lysates of primary samples from patients with T-ALL (left panel) or ETP-ALL, near-ETP, and ETP/Myeloid ALL (right panel) or from xenograft-passaged ETP-ALL patient samples (ETP PDX, bottom panel) were probed for MERTK and BCL-2. Tubulin was used as a loading control.